Ohm Drug Patent Portfolio
Ohm's Family Patents
Recent FDA approvals and tentative approvals for Ohm
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Sodium Oxybate |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 19 Jan, 2017 |
Clinical Trials
Recent Clinical Trials by Ohm:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008) | Merck Sharp & Dohme LLC | NA |
COMPLETED
(Jan, 2019)
| PHASE2 |
| A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004) | Merck Sharp & Dohme LLC | NA |
TERMINATED
(Dec, 2018)
| PHASE1 |
| A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014) | Merck Sharp & Dohme LLC | NA |
COMPLETED
(Dec, 2018)
| PHASE1 |
| A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013) | Merck Sharp & Dohme LLC | NA |
COMPLETED
(Dec, 2018)
| PHASE1 |
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List